共轭体系
医学
配体(生物化学)
药理学
概念证明
化学
癌症研究
内科学
受体
计算机科学
操作系统
有机化学
聚合物
出处
期刊:Diabetes
[American Diabetes Association]
日期:2025-06-13
卷期号:74 (Supplement_1)
摘要
Introduction and Objective: ALK7 plays a crucial role in adipose homeostasis, with genetic variants linked to obesity in human GWAS. This study examines the pharmacodynamic effects of SGB-ALK7 in cynomolgus monkeys and its therapeutic potential in an obese mouse model. Methods: SanegeneBio is developing Ligand and Enhancer Assisted Delivery (LEAD™) technology, which utilizes a receptor-mediated internalization mechanism to power biodistribution to adipocytes and de-target liver. Based on this platform, SGB-ALK7s were developed to degrade and silence ALK7 in the adipose tissues of mice and monkeys, respectively. Results: We demonstrate durable and tissue-selective adipocyte mRNA inhibition after administration of a single S.C. dose in nonhuman primates. In DIO mice, a research analog of SGB-ALK7 resulted in body weight loss comparable to Semaglutide but with near-complete preservation of lean mass. Notably, we observed significantly reduced long-term body weight gain after Semaglutide withdrawal. Furthermore, SGB-ALK7 boosted Semaglutide's weight-loos effects, achieving full efficacy at 1/3 of the standard dose. Conclusion: SGB-ALK7 is a potent siRNA therapeutic that silences adipose ALK7, reduces fat mass while preserving lean mass, and promotes weight loss, supporting the clinical development of SGB-ALK7, along with other adipocyte-targeted LEAD™ siRNAs, for the treatment of obesity. Disclosure P. Zhang: None.
科研通智能强力驱动
Strongly Powered by AbleSci AI